Interferon-α-2b Reactions 1680, p185 - 2 Dec 2017 Various toxicities: 2 case reports In a retrospective, single-center study of 14 patients, 2 patients [ages not stated, not all sexes stated] were described. Out of whom, one patient developed grade 2 weight loss and other one female developed fever, lymphopenia, anaemia, thoracic pain, hypertension, pulmonary oedema and renal insufficiency along with cardiac arrest during treatment with Both patients had a history of malignant pheochromocytoma/paraganglioma (MPPGL) and they received interferon-α-2b for its treatment. They received SC interferon-α-2b injection 1.5 MU, thrice in a week, 28 day cycle. In one patient interferon-α-2b dose was reduced as the patient developed grade 2 weight loss. The other patient (female) was admitted to the ICU one month after the therapy discontinuation due to fever, lymphopenia and anaemia without any evidence of infectious disease. In addition to this, she complained of hypertension, pulmonary oedema, thoracic pain and renal insufficiency. Thereafter her condition exacerbated and she died because of cardiac arrest. Disease progression was also hypothesised as a cause of death [duration of treatment to reactions onsets not stated; outcome of other ADRs prior to death not stated]. Author comment: "The [interferon]-alpha dose was reduced in four patients: because of asthenia in three patients (one grade 2 and two grade 3) and because of grade 2 weight loss in one patient." "One patient was admitted to the intensive care unit 1 month after [interferon]-alpha discontinuation because of fever, lymphopenia, and anemia with no evidence of infectious disease and normal blood pressure." Hadoux J, et al. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients. Hormones and Cancer 8: 330-337, No. 5, Dec 2017. Available from: URL: - France 803285003 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial